The Swedish real-world study reported at AAIC 2026 tested C2N Diagnostics' PrecivityAD2 blood test in 1,310 patients with cognitive impairment. It found primary-care accuracy rose to match specialists, a result with direct relevance for younger-onset Alzheimer's families. Younger-onset Alzheimer's means symptoms that begin before age 65. PrecivityAD2 is a blood test that measures amyloid-beta 42/40 and phosphorylated-tau 217 ratios to estimate amyloid pathology from a single blood draw.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the Swedish team study?
- How accurate was the blood test?
- Did results change patient care?
- What does this mean before age 65?
What did the Swedish team study?
Lund University neurologist Sebastian Palmqvist led the study with 1,310 patients and 165 primary-care and specialty physicians. The Alzheimer's Association AAIC press release reports that scale and leadership in its conference summary AAIC 2026 press release.
The team tested PrecivityAD2 during routine evaluation of cognitive impairment. The same Alzheimer's Association release describes the test as a single-draw measure of amyloid-beta and tau ratios.
How accurate was the blood test?
Primary-care physicians improved from about 65% diagnostic accuracy before results to 93% after. AJMC reports that post-test score nearly matched dementia specialists at about 90-94% AJMC FDA clearance report.
The pattern favored local triage. Pharmaceutical Technology reports the test was especially useful for primary-care doctors to rule out Alzheimer's disease Pharmaceutical Technology early-diagnostics report.
Did results change patient care?
Physicians changed the working diagnosis in about one-third of patients, including 30% in primary care. They altered future care or testing plans in more than half of cases.
That shift supports faster triage and fewer unnecessary referrals. Specialists also used the result to confirm Alzheimer's, which helps direct the right patients to specialty care sooner.
What does this mean before age 65?
Working-age adults often face long waits for dementia evaluation. Accurate local testing can shorten the path to diagnosis, workplace planning, and family care decisions. The AAIC report was interim conference data in largely older mild-impairment and dementia groups, not a trial limited to disease before age 65.
Families should treat the findings as strong support for primary-care testing, not proof of equal performance in younger adults. FDA clearance on Aug. 20, 2026 made PrecivityAD2 available as an aid, not a stand-alone diagnosis, for symptomatic adults age 40 and older undergoing clinical evaluation. AJMC reports that age coverage directly includes younger-onset families AJMC FDA clearance report.
- Ask a primary-care doctor about evaluation for persistent memory, thinking, or work-performance changes
- Bring a timeline of symptoms, medications, sleep changes, and family history
- Ask whether a blood biomarker test fits the current clinical evaluation
- Plan next steps for driving, work duties, finances, and support needs while awaiting results
You Might Also Like
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: A Source-Checked Briefing for Younger-Onset Alzheimer’s Families
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Younger-Onset Alzheimer’s Families
